Recent advances in Charcot-Marie-Tooth disease

Current Opinion in Neurology

Volumn 27, Issue 5, 2014, Pages 532-540

  Baets, Jonathan ^a,b,c   De Jonghe, Peter ^a,b,c   Timmerman, Vincent ^a,b  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b UNIVERSITY OF ANTWERP   (Belgium)

^c ANTWERP UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Charcot Marie Tooth disease; Clinical and molecular genetics; Inherited peripheral neuropathy; Next generation sequencing; Peripheral nervous system

Indexed keywords

ASCORBIC ACID; CURCUMIN; HISTONE DEACETYLASE 6; HISTONE DEACETYLASE INHIBITOR; LONAPRISAN;

CLINICAL TRIAL (TOPIC); GENETIC SCREENING; GENETIC VARIABILITY; HEREDITARY MOTOR SENSORY NEUROPATHY; HUMAN; NEUROLOGIST; NEUROMUSCULAR DISEASE; NEXT GENERATION SEQUENCING; OUTCOME ASSESSMENT; PERIPHERAL NEUROPATHY; PHENOTYPE; REVIEW; CHARCOT-MARIE-TOOTH DISEASE; GENETIC PREDISPOSITION; GENETICS;

CHARCOT-MARIE-TOOTH DISEASE; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; HUMANS;

EID: 84925854702     PISSN: 13507540     EISSN: 14736551     Source Type: Journal    
DOI: 10.1097/WCO.0000000000000131     Document Type: Review

References (62)

1. Martyn CN, Hughes RA. Epidemiology of peripheral neuropathy. J Neurol Neurosurg Psychiatry 1997;62:310-318.
2. Pareyson D, Scaioli V, Laura M. Clinical and electrophysiological aspects of Charcot-Marie-Tooth disease. Neuromolecular Med 2006;8:3-22.
3. Pareyson D, Marchesi C. Diagnosis, natural history, and management of Charcot-Marie-Tooth disease. Lancet Neurol 2009;8:654-667.
4. Harding AE, Thomas PK. The clinical features of hereditary motor and sensory neuropathy types I and II. Brain 1980;103:259-280.
5. Schröder JM. Neuropathology of Charcot-Marie-Tooth and related disorders. Neuromolecular Med 2006;8:23-42.
6. England JD, Gronseth GS, Franklin G, et al. Evaluation of distal symmetric polyneuropathy: the role of laboratory and genetic testing (an evidence-based review). Muscle Nerve 2009;39:116-125.
7. Saporta AS, Sottile SL, Miller LJ, et al. Charcot-Marie-Tooth disease subtypes and genetic testing strategies. Ann Neurol 2011;69:22-33.
8. Nicholson G, Myers S. Intermediate forms of Charcot-Marie-Tooth neuropathy: a review. Neuromolecular Med 2006;8:123-130.
9. Szigeti K, Nelis E, Lupski JR. Molecular diagnostics of Charcot-Marie-Tooth disease and related peripheral neuropathies. Neuromolecular Med 2006;8:243-254.
10. Dubourg O, Azzedine H, Verny C, et al. Autosomal-recessive forms of demyelinating Charcot-Marie-Tooth disease. Neuromolecular Med 2006;8:75-86.
11. Pitceathly RD, Murphy SM, Cottenie E, et al. Genetic dysfunction of MT-ATP6 causes axonal Charcot-Marie-Tooth disease. Neurology 2012;79:1145-1154.
12. Baets J, Deconinck T, De Vriendt E, et al. Genetic spectrum of hereditary neuropathies with onset in the first year of life. Brain 2011;134:2664-2676.
13. Shy ME, Jani A, Krajewski K, et al. Phenotypic clustering in MPZ mutations. Brain 2004;127:371-384.
14. Rossor AM, Polke JM, Houlden H, Reilly MM. Clinical implications of genetic advances in Charcot-Marie-Tooth disease. Nat Rev Neurol 2013;9:562-571. An exhaustive overview of the current genetic spectrum of all forms of inherited peripheral neuropathies and implications for genetic testing in a clinical context.
15. Raeymaekers P, Timmerman V, Nelis E, et al. Duplication in chromosome 17p11.2 in Charcot-Marie-Tooth neuropathy type 1a (CMT 1a). The HMSN collaborative research group. Neuromuscul Disord 1991;1:93-97.
16. Lupski JR, De Oca-Luna RM, Slaugenhaupt S, et al. DNA duplication associated with Charcot-Marie-Tooth disease type 1A. Cell 1991;66:219-232.
17. Timmerman V, Strickland AV, Zuchner S. Genetics of Charcot-Marie-Tooth (CMT) disease withinthe frame ofthe human genome project success. Genes (Basel) 2014;5:13-32.
18. Nakhro K, Park JM, Hong YB, et al. SETbinding factor1 (SBF1) mutation causes Charcot-Marie-Tooth disease type 4B3. Neurology 2013;81:165-173.
19. Xu WY, Gu MM, Sun LH, et al. A nonsense mutation in DHTKD1 causes Charcot-Marie-Tooth Disease type 2 in a large Chinese pedigree. Am J Hum Genet 2012;91:1088-1094.
20. Ishiura H, Sako W, Yoshida M, et al. The TRK-fused gene is mutated in hereditary motor and sensory neuropathy with proximal dominant involvement. Am J Hum Genet 2012;91:320-329.
21. Beetz C, Johnson A, Schuh AL, et al. Inhibition of TFG function causes hereditary axon degeneration by impairing endoplasmic reticulum structure. Proc Natl Acad Sci U S A 2013;110:5091-5096.
22. Gonzalez M, McLaughlin H, Houlden H, et al. Exome sequencing identifies a significant variant in methionyl-tRNA synthetase (MARS) in a family with lateonset CMT2. J Neurol Neurosurg Psychiatry 2013;84:1247-1249.
23. Vester A, Velez-Ruiz G, McLaughlin HM, et al. A loss-of-function variant in the human histidyl-tRNA synthetase (HARS) gene is neurotoxic in vivo. Hum Mutat 2013;34:191-199.
24. Novarino G, Fenstermaker AG, Zaki MS, et al. Exome sequencing links corticospinal motor neuron disease to common neurodegenerative disorders. Science 2014;343:506-511. A highly interesting and large-scale study showing the sheer strength of NGS technologies, identifying no fewer than 18 novel genes of hereditary spastic paraplegia in a single study.
25. Zimon M, Baets J, Almeida-Souza L, et al. Loss-of-function mutations in HINT1 cause axonal neuropathy with neuromyotonia. Nat Genet 2012;44:1080-1083.
26. Ylikallio E, Poyhonen R, Zimon M, et al. Deficiency of the E3 ubiquitin ligase TRIM2 in early-onset axonal neuropathy. Hum Mol Genet 2013;22:2975-2983.
27. Rinaldi C, Grunseich C, Sevrioukova IF, et al. Cowchock syndrome is associated with a mutation in apoptosis-inducing factor. Am J Hum Genet 2012;91:1095-1102.
28. Kennerson ML, Yiu EM, Chuang DT, et al. A new locus for X-linked dominant Charcot-Marie-Tooth disease (CMTX6) is causedbymutationsin the pyruvate dehydrogenase kinase isoenzyme 3 (PDK3) gene. Hum Mol Genet 2013;22:1404-1416.
29. Soong BW, Huang YH, Tsai PC, et al. Exome sequencing identifies GNB4 mutations as a cause of dominant intermediate Charcot-Marie-Tooth disease. Am J Hum Genet 2013;92:422-430.
30. Azzedine H, Zavadakova P, Plante-Bordeneuve V, et al. PLEKHG5 deficiency leads to an intermediate form of autosomal-recessive Charcot-Marie-Tooth disease. Hum Mol Genet 2013;22:4224-4232.
31. Baulac S, Lenk GM, Dufresnois B, et al. Role of the phosphoinositide phosphatase FIG4 gene in familial epilepsy with polymicrogyria. Neurology 2014;82:1068-1075.
32. Campeau PM, Lenk GM, Lu JT, et al. Yunis-Varon syndrome is caused by mutations in FIG4, encoding a phosphoinositide phosphatase. Am J Hum Genet 2013;92:781-791.
33. Lupski JR, Reid JG, Gonzaga-Jauregui C, et al. Whole-genome sequencing in a patient with Charcot-Marie-Tooth neuropathy. N Engl JMed 2010;362:1181-1191.
34. Montenegro G, Powell E, Huang J, et al. Exome sequencing allows for rapid gene identification in a Charcot-Marie-Tooth family. Ann Neurol 2011;69:464-470.
35. Tousignant R, Trepanier A, Shy ME, Siskind CE. Genetic testing practices for Charcot-Marie-Tooth type 1A disease. Muscle Nerve 2014;49:478-482.
36. Klein CJ, Middha S, Duan X, et al. Application of whole exome sequencing in undiagnosed inherited polyneuropathies. J Neurol Neurosurg Psychiatry 2014. [Epub ahead of print] A very recent in-depth study showing the systematic use of WES in genetically undefined inherited peripheral neuropathies. In addition, the authors give a critical view on the future prospects for these techniques.
37. Schabhuttl M, Wieland T, Senderek J, et al. Whole-exome sequencing in patients with inherited neuropathies: outcome and challenges. J Neurol 2014;261:970-982. Another study applying WES to genetically unresolved inherited peripheral neuropathies, nicely illustrating several issues of data analysis and unexpected findings in unusual phenotypes.
38. Baets J, Timmerman V. Inherited peripheral neuropathies: a myriad of genes and complex phenotypes. Brain 2011;134:1587-1590.
39. Klein CJ, Bird T, Ertekin-Taner N, et al. DNMT1 mutation hot spot causes varied phenotypes of HSAN1 with dementia and hearing loss. Neurology 2013;80:824-828.
40. Kornak U, Mademan I, Schinke M, et al. Sensory neuropathy with bone destruction due to a mutation in the membrane-shaping atlastin GTPase 3. Brain 2014;137:683-692.
41. Timmerman V, Clowes VE, Reid E. Overlapping molecular pathological themes link Charcot-Marie-Tooth neuropathies and hereditary spastic paraplegias. Exp Neurol 2013;246:14-25. This systematic literature overview explores the growing areas of genetic, cellbiological and clinical overlap between two seemingly distinct groups of 'long axonopathies', namely the hereditary spastic paraplegias and the inherited peripheral neuropathies.
42. Auer-Grumbach M, Weger M, Fink-Puches R, et al. Fibulin-5 mutations link inherited neuropathies, age-related macular degeneration and hyperelastic skin. Brain 2011;134:1839-1852.
43. Mademan I, Deconinck T, Dinopoulos A, et al. De novo INF2 mutations expand the genetic spectrum of hereditary neuropathy with glomerulopathy. Neurology 2013;81:1953-1958. Recent expansion of the genetic and clinical spectrum of INF2-associated CMT and focal segmental glomerulosclerosis.
44. Amato AA, Reilly MM. The death panel for Charcot-Marie-Tooth panels. Ann Neurol 2011;69:1-4.
45. Liebaers I, Desmyttere S, Verpoest W, et al. Report on a consecutive series of 581 children born after blastomere biopsy for preimplantation genetic diagnosis. Hum Reprod 2010;25:275-282.
46. Passage E, Norreel JC, Noack-Fraissignes P, et al. Ascorbic acid treatment corrects the phenotype of a mouse model of Charcot-Marie-Tooth disease. Nat Med 2004;10:396-401.
47. Burns J, Ouvrier RA, Yiu EM, et al. Ascorbic acid for Charcot-Marie-Tooth disease type 1A in children: a randomised, double-blind, placebo-controlled, safety and efficacy trial. Lancet Neurol 2009;8:537-544.
48. Lewis RA, McDermott MP, Herrmann DN, et al., Muscle Study Group. High-dosage ascorbic acid treatment in Charcot-Marie-Tooth disease type 1A: results of a randomized, double-masked, controlled trial. JAMA Neurol 2013;70:981-987. The most recently reported trial, studying the effects of high-dose ascorbic acid on disease severity and progression during a 2-year trial in CMT1A patients.
49. Micallef J, Attarian S, Dubourg O, et al. Effect of ascorbic acid in patients with Charcot-Marie-Tooth disease type 1A: a multicentre, randomised, doubleblind, placebo-controlled trial. Lancet Neurol 2009;8:1103-1110.
50. Pareyson D, Solari A. Charcot-Marie-Tooth disease type 1A: is ascorbic acid effective? Lancet Neurol 2009;8:1075-1077.
51. Pareyson D, Reilly MM, Schenone A, et al., CMT-TRIAAL, CMT-TRAUK. Ascorbic acid in Charcot-Marie-Tooth disease type 1A (CMT-TRIAAL and CMT-TRAUK): a double-blind randomised trial. Lancet Neurol 2011;10:320-328.
52. Shy ME, Blake J, Krajewski K, et al. Reliability and validity of the CMT neuropathy score as a measure of disability. Neurology 2005;64:1209-1214.
53. Shy ME, Chen L, Swan ER, et al. Neuropathy progression in Charcot-Marie-Tooth disease type 1A. Neurology 2008;70:378-383.
54. Haberlova J, Seeman P. Utility of Charcot-Marie-Tooth neuropathy score in children with type 1A disease. Pediatr Neurol 2010;43:407-410.
55. Burns J, Menezes M, Finkel RS, et al. Transitioning outcome measures: relationship between the CMTPedS and CMTNSv2 in children, adolescents, and young adults with Charcot-Marie-Tooth disease. J Peripher Nerv Syst 2013;18:177-180.
56. Murphy SM, Herrmann DN, McDermott MP, et al. Reliability of the CMT neuropathy score (second version) in Charcot-Marie-Tooth disease. J Peripher Nerv Syst 2011;16:191-198.
57. Fledrich R, Schlotter-Weigel B, Schnizer TJ, et al. A rat model of Charcot-Marie-Tooth disease 1A recapitulates disease variability and supplies biomarkers of axonal loss in patients. Brain 2012;135:72-87.
58. Sereda MW, Meyer Zu Horste G, Suter U, et al. Therapeutic administration of progesterone antagonist in a model of Charcot-Marie-Tooth disease (CMT-1A). Nat Med 2003;9:1533-1537.
59. Prukop T, Epplen DB, Nientiedt T, et al. Progesterone antagonist therapy in a Pelizaeus-Merzbacher mouse model. Am J Hum Genet 2014;94:533-546. A very recent study using lonaprisan, a progesterone antagonist in Pelizaeus-Merzbacher disease. This myelin disorder of the central nervous system has many similarities with CMT1A. An analogue, onapristone, was previously shown to be beneficial in a CMT1A rat model, but this progesterone antagonist has an unfavorable safety profile in humans.
60. Khajavi M, Shiga K, Wiszniewski W, et al. Oral curcumin mitigates the clinical and neuropathologic phenotype of the Trembler-J mouse: a potential therapy for inherited neuropathy. Am J Hum Genet 2007;81:438-453.
61. Patzko A, Bai Y, Saporta MA, et al. Curcumin derivatives promote Schwann cell differentiation and improve neuropathy in R98C CMT1B mice. Brain 2012;135:3551-3566. Treatment with curcumin improves the neuropathy phenotype in a mouse model of CMT caused by mutations in myelin protein zero (MZP).
62. D'Ydewalle C, Krishnan J, Chiheb DM, et al. HDAC6 inhibitors reverse axonal loss in a mouse model of mutant HSPB1-induced Charcot-Marie-Tooth disease. Nat Med 2011;17:968-974.